Welcome to our dedicated page for Keros Therapeutics news (Ticker: KROS), a resource for investors and traders seeking the latest updates and insights on Keros Therapeutics stock.
Keros Therapeutics, Inc. (Nasdaq: KROS) is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders. The company’s mission focuses on addressing high unmet medical needs through innovative therapeutic solutions.
At the forefront of Keros’ pipeline is KER-050, a protein therapeutic product candidate aimed at treating low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes (MDS) and myelofibrosis. KER-050 is currently in Phase 2 clinical trials, with promising data presented at the 65th American Society of Hematology meeting showcasing its potential to ameliorate ineffective hematopoiesis and improve patient outcomes.
Another key product in development is KER-012, a small molecule being developed for the treatment of pulmonary arterial hypertension (PAH) and cardiovascular disorders. This candidate is also in Phase 2 trials and has shown encouraging preliminary results, particularly in treating bone loss disorders such as osteoporosis and osteogenesis imperfecta.
KER-047, another small molecule candidate, targets anemia and the rare genetic disorder, fibrodysplasia ossificans progressiva (FOP). Currently in Phase 1 clinical trials, KER-047 aims to address significant gaps in treatment for these conditions.
Financially, Keros reported a net loss of $39.4 million for the third quarter of 2023, attributed to increased research and development efforts. Despite this, the company maintains a solid cash balance of $287.9 million as of September 30, 2023, expected to fund operations into the fourth quarter of 2025. The recent public offering of $120 million in common stock further strengthens their financial position.
Keros’ strategic partnerships and collaborations play a crucial role in its development strategy. The company’s agreement with Hansoh (Shanghai) Healthtech Co., Ltd. in 2021 for manufacturing technology transfer is a significant step towards commercial scalability.
The company’s commitment to advancing its pipeline and achieving clinical milestones is evident through its continuous updates and transparent communication with stakeholders. Upcoming milestones include updates on the KER-050 and KER-012 programs, reflecting Keros’ proactive approach in driving innovation and improving patient lives.
Keros Therapeutics remains a leader in leveraging the transforming growth factor-beta (TGF-β) family of proteins, aiming to provide meaningful and potentially disease-modifying benefits to patients.
Keros Therapeutics, Inc. (Nasdaq: KROS) announced preliminary results from its Phase 2 trial of KER-050 for treating anemia and thrombocytopenia in patients with myelodysplastic syndromes. As of May 14, 2021, twelve patients were treated, with five achieving significant hematological endpoints. The drug was well tolerated, with no serious drug-related adverse events reported. Based on the results, Keros will extend the trial duration to up to two years and initiate further trial phases. A conference call is scheduled for June 23, 2021, to discuss these findings.
Keros Therapeutics (KROS) presented significant preclinical data at the EHA2021 Virtual Congress, highlighting the efficacy of ALK2 inhibition and the novel therapy KER-050. Studies showed that ALK2 inhibition reduced hepcidin levels and improved iron homeostasis in models of anemia and iron overload. KER-050 exhibited rapid and sustainable effects on erythropoiesis and increased erythropoietin levels, supporting its potential as a treatment for myelodysplastic syndromes and myelofibrosis. Results indicate promising therapeutic avenues for conditions related to elevated hepcidin.
Keros Therapeutics, Inc. (Nasdaq: KROS) announced that its President and CEO, Jasbir S. Seehra, Ph.D., will present at the Jefferies Virtual Healthcare Conference on June 1 at 2:00 PM EST. The presentation will be available via a live webcast and will also be archived on Keros' Investors section for 90 days. Keros focuses on developing innovative treatments for hematological and musculoskeletal disorders, with key product candidates including KER-050 for cytopenias, KER-047 for anemia from iron imbalance, and KER-012 for bone loss and pulmonary arterial hypertension.
Keros Therapeutics, Inc. (Nasdaq: KROS) announced the issuance of U.S. Patent No. 11,013,785, a foundational patent for novel therapeutic proteins, including KER-050. This patent is critical for Keros' wholly-owned internal programs and extends patent protection until at least November 2037. KER-050 is designed to treat cytopenias like anemia in patients with myelodysplastic syndromes and myelofibrosis. Keros plans to enhance its patent portfolio to support its expanding pipeline of hematological and musculoskeletal treatments.
Keros Therapeutics (Nasdaq: KROS) announced promising results from a preclinical study of KER-012 targeting pulmonary arterial hypertension (PAH) at the American Thoracic Society International Conference. The study demonstrated that KER-012 prevented markers of inflammation, fibrosis, and vascular remodeling in a rodent PAH model. Notably, the treatment reduced right ventricle and arterial wall thickness without increasing red blood cell counts, indicating potential for safe treatment of PAH. KER-012 could also enhance signaling pathways involved in bone disorders and PAH.
Keros Therapeutics (Nasdaq: KROS) announced the presentation of four abstracts from its KER-050 and ALK2 programs at the upcoming 26th Annual Congress of the European Hematology Association, taking place virtually from June 9-17, 2021. Findings include promising preclinical data on KER-050's ability to promote red blood cell production, relevant for conditions like myelodysplastic syndromes. The company is on track to report initial data from its Phase 2 clinical trial of KER-050 by the end of June 2021, solidifying its commitment to addressing hematological disorders.
Keros Therapeutics, Inc. (Nasdaq: KROS) reported a net loss of $15.9 million for Q1 2021, up from $11.9 million in Q1 2020, primarily due to increased research and development efforts. R&D expenses rose to $11.5 million, driven by activities related to KER-012 and higher personnel costs. General and administrative costs also increased to $4.3 million, reflecting organizational growth. Cash reserves stood at $255.2 million, expected to fund operations through Q4 2023. The company is advancing various clinical trials, including a Phase 2 trial of KER-050, with initial results anticipated mid-2021.
Keros Therapeutics (KROS) announced a business update and 2020 financial results, highlighting significant progress in clinical trials and a successful public offering. The fourth quarter net loss was $10.7 million, with a total loss of $45.4 million for the year, up from $12.3 million in 2019. R&D expenses totaled $9.7 million for Q4 and $33.9 million for 2020, reflecting increased activities. As of December 31, 2020, cash and equivalents stood at $265.9 million, securing operational funding into Q4 2023. Upcoming milestones include new trials for KER-050 and KER-047.
Keros Therapeutics (Nasdaq: KROS) presented preclinical results of KER-050 and its ALK2 inhibitor program at the ESH Translational Research E-Conference. The data supports a rapid hematological response and durable effects observed during Phase 1 trials, indicating potential for treating anemia due to ineffective erythropoiesis, particularly in myelodysplastic syndromes and myelofibrosis. Notable increases in red blood cells (7%) and hemoglobin (6.7%) were observed in mice after treatment with RKER-050, demonstrating promise in addressing hepcidin-mediated anemia and enhancing iron availability.
Keros Therapeutics, Inc. (Nasdaq: KROS), a clinical-stage biopharmaceutical company, will have its President and CEO, Jasbir S. Seehra, Ph.D., present at the H.C. Wainwright Global Life Sciences 2021 Virtual Conference on March 9, 2021, starting at 7:00 am ET. The presentation will focus on Keros' advancements in treatments for hematological and musculoskeletal disorders. Investors can access the live presentation and subsequent replays for 90 days via the company’s website.
FAQ
What is the current stock price of Keros Therapeutics (KROS)?
What is the market cap of Keros Therapeutics (KROS)?
What is Keros Therapeutics’ main focus?
What are the key products in Keros Therapeutics’ pipeline?
What recent achievements has Keros Therapeutics reported?
What is the financial condition of Keros Therapeutics?
How is Keros Therapeutics advancing its clinical trials?
What partnerships does Keros Therapeutics have?
What disorders does KER-050 target?
What is the significance of Fast Track designation for KER-050?
When can we expect updates on KER-012?
What role does the TGF-β family of proteins play in Keros Therapeutics’ research?
